TriSalus Life Sciences (NASDAQ:TLSI) Receives “Buy” Rating from Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a report released on Friday,Benzinga reports. The brokerage currently has a $11.00 price target on the stock.

TLSI has been the topic of a number of other research reports. Cantor Fitzgerald began coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price objective on the stock. Lake Street Capital began coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Roth Mkm reiterated a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, TriSalus Life Sciences has a consensus rating of “Buy” and a consensus target price of $11.56.

TriSalus Life Sciences Stock Performance

NASDAQ:TLSI opened at $5.62 on Friday. The firm has a 50-day simple moving average of $5.40 and a 200-day simple moving average of $4.74. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42. The firm has a market cap of $171.37 million, a P/E ratio of -2.26 and a beta of 0.48.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.35) EPS for the quarter, hitting analysts’ consensus estimates of ($0.35). The business had revenue of $8.26 million during the quarter, compared to the consensus estimate of $8.12 million. On average, research analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Mary T. Szela bought 4,826 shares of TriSalus Life Sciences stock in a transaction that occurred on Monday, January 27th. The stock was bought at an average price of $5.42 per share, for a total transaction of $26,156.92. Following the purchase, the chief executive officer now directly owns 429,503 shares of the company’s stock, valued at approximately $2,327,906.26. The trade was a 1.14 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James Emmett Young purchased 6,000 shares of the company’s stock in a transaction on Wednesday, February 5th. The shares were purchased at an average price of $5.65 per share, for a total transaction of $33,900.00. Following the purchase, the chief financial officer now owns 30,000 shares in the company, valued at approximately $169,500. The trade was a 25.00 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 54,856 shares of company stock valued at $294,608. Insiders own 32.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares during the last quarter. MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences in the third quarter worth $184,000. Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences in the third quarter worth $66,000. Bank of America Corp DE raised its holdings in shares of TriSalus Life Sciences by 120,471.6% during the fourth quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock worth $894,000 after purchasing an additional 178,298 shares during the last quarter. Finally, Northern Trust Corp lifted its position in TriSalus Life Sciences by 22.7% during the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock valued at $161,000 after purchasing an additional 5,936 shares during the period. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.